FDA Brief

Warning letters Food

FDA warning letter to

Mountain Peak Nutritionals

LowIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA says Mountain Peak Nutritionals' Mood Support is an unapproved drug and illegally labeled over claims it treats depression and anxiety.

What happened

FDA reviewed www.mountainpeaknutritionals.com in December 2020 and found the company takes orders there for Mood Support. The website and technical data sheet claimed ingredients treat depression and anxiety, including comparing 5-HTP to antidepressant drugs. FDA says those claims make Mood Support a drug, but it is not FDA-approved and lacks adequate directions for use.

What FDA found

  1. FDA says website claims that Mood Support treats depression and anxiety make it a drug intended to cure, mitigate, treat, or prevent disease.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. FDA says Mood Support is an unapproved new drug because it is not generally recognized as safe and effective for those uses and has no FDA approval.

    section 201(p) of the Act [21 U.S.C. § 321(p)]; sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  3. FDA says Mood Support is misbranded (improperly labeled) because it lacks adequate directions for safe lay use, since its intended uses need a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  4. FDA says introducing the misbranded drug into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA tells the company to take prompt action and notify FDA in writing within fifteen working days of receipt, describing the specific steps taken, how recurrence will be prevented, and providing related documents. If it believes there is no violation, it must explain why with supporting information.

Who should pay attention

  • supplement companies making depression or anxiety claims
  • retailers and online marketplaces that list Mood Support-type products
  • marketing teams that compare supplements to prescription antidepressants

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk